The Effects of Miminal Stimulation Protocol on Preimplantation Genetic Screening

January 31, 2022 updated by: Gokalp Oner

The Effects of Miminal Stimulation Protocol on Clinical Outcomes of Advanced Maternal Aged Women With Preimplantation Genetic Screening

PGS has been the most effective method for embryo selection in IVF cycles. Euploidy rates decrease significantly with advancing maternal age (AMA). The dosage of gonadotropins also may be increased to recruit an adequate number of follicles in AMA women, minimal Stimulation Protocol (MSP) with the new combination of human menopausal gonadotrophin (hMG) and clomiphene citrate (CC) for controlled ovarian hyperstimulation is defined for poor ovarian response women. The aim of this study is to show minimal stimulation protocol affect euploidy and pregnancy rates in preimplatation genetic screening (PGS) cycles with single embryo transfer.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
    • Gevher Nesibe
      • Kayseri, Gevher Nesibe, Turkey, 38039
        • Not yet recruiting
        • Gokalp Oner
        • Contact:
      • Kayseri, Gevher Nesibe, Turkey, 38039
        • Recruiting
        • Gokalp Oner
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

38 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Probability Sample

Study Population

200 advanced maternal aged women

Description

Inclusion Criteria: Advanced maternal aged -

Exclusion Criteria: Severe male factor, endometriosis, and absolute tubal factor were excluded in this study.

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
100 patients with minimal
In advancing maternal age (AMA) women, minimal stimulation protocol (MSP) with the new combination of human menopausal gonadotrophin (hMG) and clomiphene citrate (CC) were performed for controlled ovarian hyperstimulation is defined for poor ovarian response women.
Genetic: protocol
ovarian stimulation protocols on euploid rates were compared.
100 patients with recombinant FSH antagonist protocol
In advancing maternal age (AMA) women, flexible antagonist protocol with recombinant FSH were performed for controlled ovarian hyperstimulation is defined for poor ovarian response women.
Genetic: protocol
ovarian stimulation protocols on euploid rates were compared.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
euploid rates
Time Frame: 3 months
the effects of different stimulation protocols on euploid rates
3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
pregnancy rates
Time Frame: 3 months
the effects of different stimulation protocols on pregnancy rates
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Gokalp Oner

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 15, 2021

Primary Completion (Anticipated)

January 23, 2022

Study Completion (Anticipated)

January 25, 2022

Study Registration Dates

First Submitted

January 31, 2022

First Submitted That Met QC Criteria

January 31, 2022

First Posted (Actual)

February 2, 2022

Study Record Updates

Last Update Posted (Actual)

February 2, 2022

Last Update Submitted That Met QC Criteria

January 31, 2022

Last Verified

January 1, 2022

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 31.01.2022

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

We can not share.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Preimplantation Genetic Screening

Clinical Trials on protocol

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe